Bézay N, Wagner L, Kadlecek V, et al. Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studies. Lancet In...
The substantial decline in the global burden of diarrhoeal diseases since 1990, particularly in children younger than 5 years, supports the effectiveness of health interventions such as oral rehydration therapy, enhanced water, sanitation, and hygiene ...
An acceptable safety and tolerability profile, confirmed parasiticidal activity, and a long half-life support progression of MMV533 into clinical trials in patients with malaria as a component of new antimalarial combination therapies.
In the past two decades artemisinin-based combination therapies have been the first-line therapy for patients with uncomplicated Plasmodium falciparum malaria globally and are the cornerstone for malaria case management in endemic countries with more t...
Using the latest data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD), the GBD 2021 Diarrhoeal Diseases Collaborators1 have published updated estimates of the global diarrhoeal disease burden in The Lancet Infectious Diseases...
Antimicrobial resistance (AMR) is predicted to outstrip malaria, HIV, and tuberculosis combined as the leading infectious cause of death by 2050. Strengthening the knowledge and evidence base for AMR with surveillance and research is one of the five ma...
The proportion of IPD due to serotypes included in PCVs in use was low in mature PCV10 and PCV13 settings. Serotype distribution differed between PCV10 and PCV13 sites and age groups. Higher-valency PCVs target most remaining IPD and are expected to ex...
Long-term use of PCV10 or PCV13 reduced IPD substantially in young children and more moderately in older ages. Non-vaccine-type serotypes increased approximately two-fold to three-fold by 6 years after introduction of PCV10 or PCV13. Continuing serotyp...
Pneumococcal conjugate vaccine (PCV) introduction has substantially reduced the global burden of pneumococcal disease and mortality. A 2019 modelling study assuming implementation in every country estimated that 13-valent PCV (PCV13) vaccination could ...
Treatment with ceftolozane–tazobactam resulted in higher rates of clinical success compared with ceftazidime–avibactam for invasive infections due to multidrug-resistant P aeruginosa. Differences were driven by improved response rates for patients with...
Pseudomonas aeruginosa is responsible for 14·3% of hospital-acquired bloodstream infections in patients in intensive care units (ICUs).1 In Europe, resistance to piperacillin–tazobactam, ceftazidime, carbapenems, fluoroquinolones, and aminoglycosides w...
The west Africa Ebola disease epidemic (2014–16) marked a historic change of course for patient care during emerging infectious disease outbreaks. The epidemic response was a failure in many ways—a slow, cumbersome, and disjointed effort by a global ar...
The west Africa Ebola disease epidemic (2014–16) marked a historic change of course for patient care during emerging infectious disease outbreaks. The epidemic response was a failure in many ways—a slow, cumbersome, and disjointed effort by a global ar...
A key lesson from the west Africa (2014–16) Ebola disease epidemic was that outbreak responses fail when they respond to patients through a narrow clinical lens without considering the broader community and social context of care. Here, in the second o...
A key lesson from the west Africa (2014–16) Ebola disease epidemic was that outbreak responses fail when they respond to patients through a narrow clinical lens without considering the broader community and social context of care. Here, in the second o...
In April, 2024, we reported on mid-season findings from NIRSE-GAL, a population-based longitudinal study on the effectiveness of universal nirsevimab prophylaxis against respiratory syncytial virus (RSV) in infants aged 0–24 months in Galicia, Spain.1 ...